Vaccines for nontypable haemophilus influenzae
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 16, 2002
Issued Date -
N/A
app pub date -
May 23, 1995
filing date -
Mar 9, 1989
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Protein 'e' of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein 'e' and peptides or proteins having a shared epitope, can be used to vaccinate against non-typable (and typable) H. influenzae and to prevent otitis media caused by H. influenzae. For this purpose, protein 'e' or derivatives thereof can be produced in native, synthetic or recombinant forms and can be administered alone or in conjunction with other antigens of H. influenzae. Protein 'e' can also be used in multivalent vaccines designed for H. influenzae and one or more other infectious organisms.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully